Navigation Links
JDRF-Helmsley Charitable Trust to fund islet encapsulation research at Diabetes Research Institute
Date:8/16/2012

New York, NY, August 16, 2012 JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell encapsulation to Dr. Camillo Ricordi, M.D. and a team of investigators at the Diabetes Research Institute (DRI), based at the University of Miami (FL).

Performed at the DRI since the 1980s, successful islet cell transplants give patients with type 1 diabetes (T1D) the ability to naturally produce their own insulin and lead healthier, more independent lives. However, only a small number of patients benefit from the procedure because of a shortage of cadaver islets, problems associated with the need for chronic immunosuppression drugs, and the low survival rate of islets immediately following implantation. The current transplant site, the liver, can be particularly inhospitable for newly implanted islets, leading to hypoxia (low oxygen) and inflammation. The number of transplants available to patients is also limited by the small number of donors and the large number of cells required for each procedure.

In the $4.6 million grant proposal being funded jointly by the JDRF-Helmsley Charitable Trust over three years, Dr. Ricordi's team will attempt to address the limitations of the requirements for immunosuppression, and the poor viability of islets, beginning with an alternate site of implantation. While the research community is exploring multiple possible alternatives, the DRI has chosen to pursue a fold in the lining of the abdomen called the omentum that the team believes will allow better access for the procedure, offer more space to accommodate delivery systems, and provide a safer environment for the newly-implanted cells.

"This is a critically important and timely support that will allow our team to remain focused on the path to a biologic cure for diabetes," Dr. Ricordi said. "The overall goal is to use a multipronged approach to address and resolve all of the outstanding issues in islet transplantation and move the field to the next level of success."

The other problem that Dr. Ricordi's team is attempting to solve is protecting the implanted cells from the body's immune response. Their approach to immunoprotection is two-fold. They will use a bioactive scaffold as a delivery system for the implanted islets that is designed to protect them from the immediate immune response. The scaffold allows the islet cells access to the surrounding blood vessels to prevent poor oxygenation, which will allow better regulation of blood sugar levels. The team is also engineering a conformal coating to encapsulate each islet to further promote long-term survival. Ultimately, the scaffold could be used to modify the immune cells in the implant local area, offering maximum protection. If successful, such technologies could remove the need for immunosuppression drugs and ensure long-term survival for the implanted cells.

"We are very excited to be supporting Dr. Ricordi's lab for this research," said JDRF Chief Scientific Officer Dr. Richard Insel. "Dr. Ricordi and colleagues have been pioneers in the area of islet cell transplantation and encapsulation, and we feel that they are well-positioned to advance an area that we hope will bring a real benefit to individuals with type 1 diabetes."


'/>"/>
Contact: Michael Cook
mcook@jdrf.org
212-479-7510
JDRF
Source:Eurekalert

Related medicine news :

1. Clemson researcher awarded nearly $245,000 to study automation trust and dependence
2. Dont Trust Dr. Google for Help on Infant Sleep Safety
3. Trust hormone oxytocin found at heart of rare genetic disorder
4. Why are elderly duped? UI researchers explain why
5. Mans Best Friend Points the Way in Genetic Research
6. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
7. By studying animal health, researchers find improved ways for developing, testing cancer therapies
8. Kolanowski earns GSAs 2012 Doris Schwartz Gerontological Nursing Research Award
9. Researchers aim to grow salivary glands using patients own cells
10. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
11. For young adults, appearance matters more than health, MU research suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... ... Will Never Be The Same” is a fictional tale about growing up with the ... the creation of published author, Kim T. Briggs, a self-described “big kid” who has ... and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama skits ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... ability of physical therapist assistants, under direct supervision of a licensed physical therapist, ... physical therapy receives a consultation and treatment plan from a licensed physical therapist ...
(Date:12/5/2016)... IL (PRWEB) , ... December 05, 2016 , ... The ... to the individual looking to buy neoprene knee sleeves for lifting and ... The design focuses heavily on two main aspects to provide a higher quality knee ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... an excellent way to ensure moisture measurements are consistently correct. However, regular ... , Now, METTLER TOLEDO offers a solution: SmartCal™ . This ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... they have teamed up with The American College of Surgeons (ACS) to provide ... on Trauma, the “Bleeding Control Basic” course is a pilot program that fulfills ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology: